Theralase Shows 24 Month Stability of Lead Anti-Cancer Drug

Theralase Technologies (TSXV:TLT; OTCQX:TLTFF) announced it demonstrated 24 months long-term stability of its lead anti-cancer Photo Dynamic Compounds (PDC) TLD-1433.
As quoted in the press release:

Stability studies are an essential component of pharmaceutical development, allowing evaluation of a drug’s stability under the influence of a variety of environmental factors such as: temperature, humidity and light. Data from these studies enable recommended storage conditions, retest intervals and shelf lives to be established.
Demonstrating long-term stability of a drug to be used in human clinical testing is essential to prove that the potency and/or efficacy of the drug is not affected during prolonged shelf life.
TLD-1433, in the most recent testing report, demonstrated that its purity has changed less than 1.7% in 24 months of long-term stability testing, indicating extreme stability of the compound.

Click here to read the full press release.

Source: www.accesswire.com